Arturo Loaiza-Bonilla, M.D.

Dr. Arturo Loaiza-Bonilla is a dedicated practicing clinician and precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institute of Health.

His major interest focuses in the field of innovative approaches to optimize clinical workflows and matching for oncology patients to  hase 1–3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based / machine learning platform, which integrates to the electronic medical record.

His company and virtual tumor board / clinical trial matching platforms have been recently featured in Genomeweb and MedPage Today, including a first-in-the-world registry SYNERGY-AI to match cancer patients based on Artificial Intelligence (https://clinicaltrials.gov/ct2/show/NCT03452774).
 
Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies at Cancer Treatment Centers of America, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles.

He is also a passionate advocate for improved access to medical care, precision oncology, technology, wearables, medical education, blockchain, organized medicine leadership and health policy, having been awarded the ‘Top 40 Under 40’ award by the Philadelphia Business Journal, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master’s in Medical Education (M.S.Ed) degree from the University of Pennsylvania.

He has held several leadership positions in state and medical societies, including his current tenure as executive board member of the Pennsylvania Society of Oncology and Hematology, and his role as President of the Board of Directors of the Global Alliance for Patient Access.